Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups

de Witte, T; Hagemeijer-Hausman, Anne; Suciu, S; Delforge, Michel; Jotterand-Bellomo, M; Tigaud, I; Belhabri, A; Aul, C; Avaido, M; Selleslag, D; Schouten, H; Ferrant, A; Amadori, S; Muus, P; Anak, O; Beeldens, F; Jansen, Jean; Hellstrom-Lindberg, E; Gratwohl, A; Willemze, R

Bone Marrow Transplantation

Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups

Author:

de Witte, T

Hagemeijer-Hausman, Anne ; Suciu, S ; Delforge, Michel ; Jotterand-Bellomo, M ; Tigaud, I ; Belhabri, A ; Aul, C ; Avaido, M ; Selleslag, D ; Schouten, H ; Ferrant, A ; Amadori, S ; Muus, P ; Anak, O ; Beeldens, F ; Jansen, Jean ; Hellstrom-Lindberg, E ; Gratwohl, A ; Willemze, R

Keywords:

Science & Technology, Life Sciences & Biomedicine, Biophysics, Oncology, Hematology, Immunology, Transplantation, 1103 Clinical Sciences, 1112 Oncology and Carcinogenesis, 3201 Cardiovascular medicine and haematology, 3211 Oncology and carcinogenesis

Bone Marrow Transplantation Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups

Author:

Keywords:

Bone Marrow Transplantation

Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups